(Q36055114)

11 August 2017

Effect of renal function on risedronate pharmacokinetics after a single oral dose (English)

1 reference

11 August 2017

1 reference

D Y Mitchell

1

1 reference

11 August 2017

J V St Peter

2

1 reference

11 August 2017

R A Eusebio

3

1 reference

11 August 2017

K A Pallone

4

1 reference

11 August 2017

S C Kelly

5

1 reference

11 August 2017

D A Russell

6

1 reference

11 August 2017

J D Nesbitt

7

1 reference

11 August 2017

G A Thompson

8

1 reference

11 August 2017

J H Powell

9

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

British Journal of Clinical Pharmacology

11 August 2017

1 reference

11 August 2017

49

1 reference

11 August 2017

3

1 reference

11 August 2017

215-222

1 reference

The effect of dosing regimen on the pharmacokinetics of risedronate

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

New markers for the determination of GFR: iohexol clearance and cystatin C serum concentration.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Human pharmacokinetics of tiludronate

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Studies of the oral bioavailability of alendronate.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Statistical estimations in pharmacokinetics.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Absorption of oral diphosphonate in normal subjects

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014925

Pharmacokinetics of clodronate in renal failure

23 September 2018

1 reference

12 December 2020

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

12 December 2020

Paget's disease of bone: reduction of disease activity with oral risedronate

1 reference

12 December 2020

Risedronate gastrointestinal absorption is independent of site and rate of administration

1 reference

12 December 2020

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

12 December 2020

Clodronate kinetics and bioavailability

1 reference

12 December 2020

1983 metropolitan height and weight tables

1 reference

12 December 2020

Antiresorptive dose-response relationships across three generations of bisphosphonates

1 reference

12 December 2020

Absolute bioavailability estimated from oral data

1 reference

12 December 2020

10.1046/J.1365-2125.2000.00135.X

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

10718776

1 reference